Dr. Lior Shaltiel reports

NUREXONE ACCEPTED INTO ARMI'S BIOFAB STARTUP LAB STRENGTHENING U.S POSITION IN REGENERATIVE MANUFACTURING

Nurexone Biologic Inc. has been accepted to the BioFab Startup Lab, part of the Advanced Regenerative Manufacturing Institute and its BioFabUSA program.

The federally supported program, launched through a grant from the U.S. Economic Development Administration, helps early-stage biotechnology companies accelerate the translation of regenerative innovations into scalable and commercially viable manufacturing.

Recent legislation and federal initiatives, including a White House bioeconomy executive order, have identified biomanufacturing as a strategic national capability for the United States and a new pillar of advanced manufacturing.

Dr. Lior Shaltiel, chief executive officer of Nurexone, noted: "Biofabrication is becoming the industrial foundation of next-generation medicine. Federal support for programs like this reflects how U.S. priorities are expanding beyond semiconductors and clean energy toward biomanufacturing. The ARMI ecosystem and infrastructure have the potential to yield longer-term commercial benefits for the company in GMP-grade U.S. exosome production and to accelerate the time to market for our products."

Nurexone's U.S. subsidiary, Exo-Top Inc., is advancing plans for the establishment of a good-manufacturing-practice-compliant facility dedicated to naive exosome production. The company believes participation in ARMI's program will enhance its value proposition to strategic partners and shareholders.

Biofabrication is the process of using living cells and biological materials to manufacture tissues and therapeutic products. It bridges the gap between scientific discovery and industrial production, creating the foundation for a new generation of regenerative medicine technologies.

About Nurexone Biologic Inc.

Nurexone is a TSX Venture Exchange-, OTCQB- and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury, both multibillion-dollar markets. Regulatory milestones, including obtaining the orphan drug designation, facilitate the road map toward clinical trials in the U.S. and Europe. Commercially, the company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. Nurexone has established Exo-Top, a U.S. subsidiary, to anchor its North American activity and growth strategy.

We seek Safe Harbor.